Table 2 CD22 expression levels and clinical parameters in ESCC tissues (n = 87)
From: CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma
Clinical parameters | CD22 | ||||||
|---|---|---|---|---|---|---|---|
Total | Expression | P-value | |||||
n | % | Negative | Positive | ||||
n | % | n | % | ||||
Total number | 87 | 100.00 | 17 | 19.54 | 70 | 80.46 | Â |
Sex | 1.000 | ||||||
 Female | 20 | 22.99 | 4 | 20.00 | 16 | 80.00 |  |
 Male | 67 | 77.01 | 13 | 19.40 | 54 | 80.60 |  |
Age | 0.592 | ||||||
 ≤ 59 | 41 | 47.13 | 9 | 21.95 | 32 | 78.05 |  |
 ≥ 60 | 46 | 52.87 | 8 | 17.39 | 38 | 82.61 |  |
Depth of tumor invasion | 0.137 | ||||||
 pT1–pT2 | 14 | 16.09 | 5 | 35.71 | 9 | 64.29 |  |
 pT3–pT4 | 73 | 83.91 | 12 | 16.44 | 61 | 83.56 |  |
Lymph node metastasis | 0.008 | ||||||
 Negative | 32 | 36.78 | 11 | 34.38 | 21 | 65.63 |  |
 Positive | 55 | 63.22 | 6 | 10.91 | 49 | 89.09 |  |
Clinical stage | Â | Â | Â | Â | Â | Â | 0.546 |
 I–II | 24 | 27.59 | 6 | 25.00 | 18 | 75.00 |  |
 III–IV | 63 | 72.41 | 11 | 17.46 | 52 | 82.54 |  |